Loading company
Just reported
Q2 FY2027 results
From Doximity's results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$174.5M
+3.6% y/y
+11% q/qGuided
$170.5M
midpoint
Above guide+2.4%EPS, GAAP
Actual
$0.18
-42% y/y
+38% q/qGuided
—
No guide given
EPS, adjusted: $0.36
Operating income, GAAP
Actual
$43.9M
-31% y/y
+31% q/qGuided
—
No guide given
Company outlook
Q3 FY2027
- Revenue$195M – $196M+5.6% y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Doximity is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.$49.4BA+
BTSGBrightSpring Health Services, Inc.$14.4BA
HNGEHinge Health, Inc.$9.9BA+
HQYHealthequity, Inc.$8.5BA+
WAYWaystar Holding Corp.$5.5BB+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Doximity, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
